Inhibition of the megakaryocyte
protein tyrosine phosphatase 2 (PTP-MEG2, also named PTPN9) activity has been shown to be a potential therapeutic strategy for the treatment of
type 2 diabetes. Previously, we reported that PTP-MEG2 knockdown enhances
adenosine monophosphate activated
protein kinase (AMPK) phosphorylation, suggesting that PTP-MEG2 may be a potential
antidiabetic target. In this study, we found that
phloridzin, isolated from Ulmus davidiana var. japonica, inhibits the catalytic activity of PTP-MEG2 (half-inhibitory concentration, IC50 = 32 ± 1.06 μM) in vitro, indicating that it could be a potential
antidiabetic drug candidate. Importantly,
phloridzin stimulated
glucose uptake by differentiated 3T3-L1 adipocytes and C2C12 muscle cells compared to that by the control cells. Moreover,
phloridzin led to the enhanced phosphorylation of AMPK and Akt relevant to increased
insulin sensitivity. Importantly,
phloridzin attenuated
palmitate-induced
insulin resistance in C2C12 muscle cells. We also found that
phloridzin did not accelerate adipocyte differentiation, suggesting that
phloridzin improves
insulin sensitivity without significant
lipid accumulation. Taken together, our results demonstrate that
phloridzin, an inhibitor of PTP-MEG2, stimulates
glucose uptake through the activation of both AMPK and Akt signaling pathways. These results strongly suggest that
phloridzin could be used as a potential therapeutic candidate for the treatment of
type 2 diabetes.